Structure Therapeutics (GPCR) Interest & Investment Income (2022 - 2026)

Structure Therapeutics' Interest & Investment Income history runs 5 years deep, the most recent figure standing at -$3.2 million for Q1 2026.

• On a quarterly basis, Interest & Investment Income fell 133.93% year-over-year to -$3.2 million in Q1 2026; TTM through Mar 2026 was $40.4 million, a 26.99% increase from a year earlier, with the FY2025 full-year figure at $35.9 million, changed 0.39% from the prior year.
• Interest & Investment Income slipped to -$3.2 million in Q1 2026 per GPCR's latest filing, from $36.0 million in the prior quarter.
• Across five years, Interest & Investment Income topped out at $36.0 million in Q4 2025 and bottomed at -$3.2 million in Q1 2026.
• The 5-year median for Interest & Investment Income is $349000.0 (2022), against an average of $4.5 million.
• Across the five-year window, Interest & Investment Income plunged 974.0% in 2023 and jumped 1667.27% in 2025, its largest moves.
• Year by year, Interest & Investment Income stood at $1.4 million in 2022, then tumbled by 40.3% to $831000.0 in 2023, then surged by 1189.77% to $10.7 million in 2024, then soared by 235.53% to $36.0 million in 2025, then slumped by 109.03% to -$3.2 million in 2026.
• Per Business Quant, the three latest GPCR Interest & Investment Income figures stand at -$3.2 million (Q1 2026), $36.0 million (Q4 2025), and $8.2 million (Q3 2025).